Chief Medical Adviser Dr. Supriya Sharma says the first signs of supply issues arose in April but it wasn't until August that companies warned their efforts to increase supplies were failing.
The treatment is approved for patients who have a moderate to high risk of recurrence, following nephrectomy or nephrectomy accompanied by surgical resection of metastatic lesions.
The federal agency says however that there are eight other drug producers offering medication with amoxicillin that are not currently reporting any issues with supply.
